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ABSTRACT
Introduction: Hypertension is a complex and multifactorial cardiovascular disorder. With different
mechanisms contributing to a different extent to an individual’s blood pressure, the discovery of
novel pathogenetic principles of hypertension is challenging. However, there is an urgent and unmet
clinical need to improve prevention, detection, and therapy of hypertension in order to reduce the
global burden associated with hypertension-related cardiovascular diseases.
Areas covered: Proteomic techniques have been applied in reductionist experimental models including
angiotensin II infusion models in rodents and the spontaneously hypertensive rat in order to unravel
mechanisms involved in blood pressure control and end organ damage. In humans proteomic studies
mainly focus on prediction and detection of organ damage, particularly of heart failure and renal
disease. While there are only few proteomic studies specifically addressing human primary hyperten-
sion, there are more data available in hypertensive disorders in pregnancy, such as preeclampsia. We
will review these studies and discuss implications of proteomics on precision medicine approaches.
Expert commentary: Despite the potential of proteomic studies in hypertension there has been
moderate progress in this area of research. Standardized large-scale studies are required in order to
make best use of the potential that proteomics offers in hypertension and other cardiovascular diseases.
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1. Introduction
Blood pressure is a physiological parameter that results from the
product of cardiac output and vascular resistance [1,2]. Depending
on the requirements of the organism, blood pressure can change
within a wide range in order to maintain perfusion pressure of
tissues and organs. While blood pressure is typically low during
periods of rest and sleep, it canbehighduringperiods of stress and
exercise. Bloodpressure also varies throughout the day depending
on hormonal and other regulatory mechanisms and it shows
longer-term variability due to seasonal and other environmental
influences [3]. In addition, some organs, including the kidneys and
the brain have sophisticated mechanisms to maintain constant
perfusion pressures irrespective of systemic blood pressure [2].
These phenomena have been subject to in-depth studies in the
systemic circulation whereas our knowledge of blood pressure
regulation in other vascular beds, for example the pulmonary
circulation is less far developed – in part due to the difficulties in
measuring pulmonary arterial pressure other than by invasive
methods.
It is apparent that this seemingly simple physiological para-
meter is much more complex than originally thought. This
complexity has implications for the definition of ‘normal’ and
‘high’ blood pressure where clearly an isolated reading at a
random time of the day cannot be used to establish the
diagnosis ‘hypertension’ [4]. In fact, hypertension is different
from many other clinical conditions whose definition is pri-
marily based on the underlying pathology, possibly combined
with diagnostic criteria based on symptoms and test results. In
contrast, hypertension is exclusively defined on a readout, and
while possible underlying mechanisms are acknowledged,
they are not part of its definition.
Unsurprisingly, the definition of hypertension has therefore
changed over the years. Where the potential harmful conse-
quences of high blood pressure have not been generally accepted
up until less than 100 years ago [5], the association between high
blood pressure cardiovascular damage and reduced lifespan
became apparent with the availability of large epidemiological
data, such as the Framingham Heart Study [6]. Definitions of
hypertension have been based on systolic, diastolic or both pres-
sures and have generally seen a higher cut-off in the past and
much lower thresholds in more recent years. While most guide-
lines still define hypertension as blood pressure above 140 mmHg
systolic and/or 90 mmHg diastolic [7–9], the most recent editions
of clinical guidelines now propose 130/80 mmHg [10], mainly
driven by a contemporary randomized clinical trial that provides
evidence for better outcome with lower blood pressure targets
[11]. It is important to note, however, that research data, as well as
guidelines acknowledge the fact that there is a continuous rela-
tionship between blood pressure level and cardiovascular risk [12]
and that thresholds and dichotomous categorizations in the first
instance serve as clinical decision tools rather than reflecting bio-
logical mechanisms. As such, the thresholds to define hyperten-
sion are driven by a number of factors, including risk and benefit of
treatment, health economic aspects, and of course trial evidence.
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Even if blood pressure is a result of cardiac output and vascular
resistance each of these factors can have multiple modulators
(Figure 1). In a minority of people with hypertension a single
distinct factor, such as activation of the renin angiotensin aldoster-
one system (RAAS) by renal artery stenosis, or production of excess
aldosterone in primary aldosteronism drives their high blood pres-
sure (secondary hypertension), whereas the majority of patients
haveprimary hypertensionwheremultiple dysregulatedpathways
together contribute to high blood pressure. It is evident that any
research into the origins of primary hypertension will result in the
discovery of multiple reasons and that by definition this condition
will have complex origins. Evidence from genome-wide associa-
tion studies has shown that despite the discovery of a large
number of genetic variants that are robustly associated with
blood pressure regulation or hypertension their absolute contribu-
tion to the phenotype remains small [13]. A complex disease with
multiple causes that is to some extent arbitrarily defined based on
a blood pressure threshold is not an easy target for research
(Figure 2). In this article we will explore whether current strategies
to unravel the origins of hypertension can benefit from proteomic
Figure 1. Key principles of blood pressure regulation. Blood pressure is the result of cardiac output and peripheral resistance where a multitude of factors
contribute to these two components. The figure illustrates some of these principles that are subject to any studies into the pathophysiology of hypertension. ADH,
antidiuretic hormone; Ang II, angiotensin II; ANP, atrial natriuretic peptide; PSNS, parasympathetic nervous system; SNS, sympathetic nervous system.
Figure 2. Challenges in hypertension that impact on proteomic studies.
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approaches. Similar to traditional approacheswewill also employ a
reductionist approach and focus on well-defined animal models
before we explore the use of proteomics in human hypertension.
We would like to emphasize that we cannot provide a systematic
review of all studies in various models of hypertension or clinical
conditions associated with hypertension. Instead we will highlight
some key papers to illustrate the development and future poten-
tial of proteomics in hypertension.
Hypertension and associated cardiovascular diseases are a
global health burden with increasing prevalence across all
continents [14–16]. Hypertension is in many cases asympto-
matic and awareness of the condition is therefore limited until
organ damage, such as stroke, myocardial infarction, or heart
failure occur. However, even those who are aware of high
blood pressure are often not receiving treatment, and blood
pressure control rates in treated patients remain low [16,17]. It
is evident that in addition to widespread use of existing
diagnostic and therapeutic options there must be novel
approaches to tackle this global problem.
2. Proteomics
We cannot provide a comprehensive overview of proteomic
techniques in this review but would like to briefly put experi-
mental and clinical data into the context of contemporary
proteomic techniques. Readers are referred to review articles
providing further background, including a recent American
Heart Association statement [18]. The term proteomics was
first coined in 1994 by Marc Wilkins as the study of an organ-
ism’s proteome at a given time [19]. Techniques involved in
proteomics include, but are not limited to, sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE), 2D-dif-
ference gel electrophoresis (2D-DIGE), immunoassays, protein
microarrays, and variations of mass spectrometry. 2D gel elec-
trophoresis was used to observe that ferritin light chain was
significantly increased in coronary artery disease [20]. 2D pro-
tein gel databases for human and other animal models have
been created and used for reference [21].
The most common analytical technique used today is nano-
flow liquid chromatography coupled to a mass spectrometer
(nLC-MS). The development of nano electrospray in 1996 by
Wilm and Mann [22] increased the sensitivity of the analysis of
biomolecules to a point were it was possible to analyze more
complex samples. Despite this, a limitation of proteomic analysis
by mass spectrometry is dynamic range; an MS is only able to
select a limited amount of ions present in a scan for further
fragmentation (MS/MS), and these ions are selected on abun-
dance. Therfore, proteins that are of interest are often not iden-
tified in complex systems. Throughout the development of mass
spectrometers advances have been made in the speed of analy-
sis allowing for an increase in the number of MS/MS events
permitted in a duty cycle. It is not uncommon today for the 20
most abundant ions in every scan to be selected for MS/MS.
However, this still means that there are many ions not selected
for MS/MS and therefore a chance at identification is lost.
Since the early 2000’s, there has been a steady stream of
technological advances that have enabled researchers to dig
further into the proteome. Subsequently, proteomics has
moved from a gel approach to a solution-based analysis. The
extraction of proteins and the preparation of samples and
their subsequent digestion to peptides in solution is the
most popular form of proteomics analysis at present. The
development of Filter-Aided Sample Preparation (FASP) com-
bines the benefits of both in-gel and in-solution digestion
strategies [23]. The addition of SDS and urea facilatates a
denaturing effect for gel electrophoresis and facilitates the
solubilization of cells and tissues. FASP has enabled research-
ers to prepare vascular tissues socu as for proteomic analysis
simply and relatively quickly [24]. Advances in samples pre-
paration have gone hand in hand with advances in instrumen-
tation. With the advances in quadrupole and time of flight
(TOF) analyzers, which have been the mainstay of proteomic
mass spectrometry since its inception, there was the introduc-
tion of new analyzers in the early 2000’s. The Orbitrap MS was
a jump in sensitivity, mass accuracy, and resolution [25]. The
original Orbitrap hardware was continually improved and
enhanced and by the time FASP was developed the LTQ
Orbitrap Velos could routinely perform 20 MS/MS per second.
However, it is important to remember that there is not one LC-
MS platform that can cover the entire proteome; the data
generated from any of the many platforms are wholly reliant
on experimental design.
There are two major approaches to proteomic analysis the
shotgun approach were samples are digested by a proteoly-
tic enzyme, usually trypsin, followed by nLC-MS/MS. In this
approach the methods are optimized for peptide separation
and chromatographic peak resolution. The other method is a
targeted approach where the mass spectrometry analysis is
targeted to the m/z of the known compound or peptide. This
analysis is only possible for the monitoring of specific known
analytes. For optimizing targeted approaches, it is not
uncommon to employ a standard of the known analyte in
order to gain information on the endogenous analyte, e.g.
charge state and retention time [26]. In cardiovascular dis-
ease both approaches have been deployed to lead to a
better global understanding of coronary artery disease [27];
or the rapid targeted analysis of the concentrations of angio-
tensin II (Ang II), Ang-(1–7), Ang III, and Ang IV [28]. In
addition it is also possible to analyze native peptides,
where no digestive enzyme is used in the preparation, such
as the diagnostic biomarkers present in urine for coronary
artery disease [29,30].
Protein quantitation studies enable researchers to ana-
lyze the changes in protein expression levels in response to
pharmacological or other stimuli or disease states. Methods
of protein quantitation include in vitro methods, such as
isobaric tags for relative and absolute quantitation (iTRAQ)
and tandem mass tags (TMT) where samples are tryptically
digested and labeled with a commercial tag. The samples
are then mixed and analyzed by nLC-MS/MS. In terms of
protein labeling, Stable Isotope Labeling with Amino acids
in Cell culture (SILAC) is the only metabolic in vivo protein
quantification method. Cells or very rarely animals are fed a
heavy labeled isotope; the experimental conditions are
therefore labeled as light, medium, or heavy from the out-
set. The samples are then mixed and prepared as one
sample. Peptide quantification is achieved on the ions
before fragmentation for peptide identification [31].
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None of these techniques, however, are possible without the
use of bioinformatics. In global shotgun analysis the spectra that
are acquired are just data. There are a multitude of software
packages both commercially available (e.g. Proteome Discoverer,
Protein Pilot, Progenesis) andopen source (for exampleMaxQuant
and the Trans-Proteomic Pipeline (TPP)) that enable proteomic
workflows to be applied to the analysis of the wide variety of
studies, including those in the cardiovascular field.
While proteomic techniques have found their way into the
study of some cardiovascular diseases [18,32], the number of
applications in hypertension remain limited. The abovementioned
limitation of some of the techniques, the dependence of results on
the type of biosamples and proteomic platforms used, and the
heterogeneity of hypertension as a clinical condition are some of
the hurdles that have to be tackled. In order to reduce the patho-
physiological complexity of hypertension, researchers are using
rodent models with well characterized forms of htypertension. We
will provide an overview of proteomic studies in two specific
models: the Ang II infusion model of hypertension and the spon-
taneously hypertensive rat (SHR).
3. Experimental models of hypertension
Many of the primary and secondary models of hypertension that
are commonly used in the study of hypertension have a dysregu-
lated RAAS, which contributes to the increased bloodpressure and
end organ damage, for example, the two kidney one clip model
[33] and SHR [34]. However, these models are complex with
hypertension and associated end organ damage developing
through the interplay of a myriad of risk factors, including genetic
influences, or the complications of mechanical injury following
surgical intervention. An experimental model that enables the
study of Ang II in isolation would facilitate proteomics studies
that could directly investigate target pathways involved in hyper-
tension in response to Ang II. The Ang II infusion model of hyper-
tension is exactly such a model.
We will therefore present a number of proteomic studies
that used the Ang II infusion model to dissect specific aspects
of hypertension and other cardiovascular diseases. In addition,
we will review studies that have been conducted in the SHR, a
widely used model of human essential hypertension and its
cardiovascular sequelae. We are aware that there are numer-
ous other preclinical models of hypertension but the choice of
these two models will illustrate the spectrum of possibilities
ranging from specific pathways (Ang II) to complex genetically
determined hypertension (SHR).
3.1. The Ang II infusion model of hypertension and end
organ damage
The RAAS regulates blood pressure through a combination of
mechanisms influencing renal electrolyte handling, vascular
smooth muscle cell (VSMC) vasoconstriction, aldosterone
release, and effects on thirst and water preservation. Renin is
released into the bloodstream and cleaves angiotensinogen to
produce Ang I, which is subsequently cleaved by angiotensin
converting enzyme (ACE) to generate Ang II [35]. Ang II has
two main receptors, the angiotensin type 1 and type 2 recep-
tors (AT1R and AT2R, respectively). Predominant effects of Ang
II are mediated via the AT1R, with the AT2R being largely
absent in normal adult tissues. Chronic RAAS activation leads
to the development of hypertension and subsequent second-
ary end organ damage through pressure overload in tissues,
such as the heart and kidney leading to cardiac hypertrophy
and fibrosis. Moreover, since the AT1R is ubiquitously
expressed Ang II can have direct effects on cardiomyocytes
and fibroblasts, further contributing to end-organ damage
[36,37]. Therapies targeting Ang II generation (ACE inhibitors)
or Ang II action (angiotensin receptor blockers; ARBs) are
mainstay treatments to reduce blood pressure and to reduce
end organ damage and subsequent morbidity and mortality in
heart failure post-myocardial infarction.
The infusionmodel of Ang II is amethod for studying the role of
Ang II in blood pressure regulation, the development of hyperten-
sion and end organ damage in isolation and has been used in a
wide rangeof rodentmodels inbothmice and rats. Normal healthy
animals are subcutaneously implanted with osmotic mini pumps
that constitutively and chronically infuse Ang II at a defined dose
[36,38]. The dose of Ang II is important to determine the type of
hypertension that develops with sub-pressor and pressor dose
models developed. Although thedosingofAng II is hugely variable
in the literature and in different models, sub-pressor doses (typi-
cally up to 200 ng/kg/min in rats administered subcutaneously
[38]) produce a gradual increase in BP over a period of approxi-
mately 1 week and peaking at 2 weeks without renal dysfunction
or sodiumorwater retention [39]. In thismodel, the bloodpressure
increases are thought to arise due to a combination of direct VSMC
vasoconstriction and oxidative stress. In contrast, infusion of
pressor doses of Ang II (greater than 200 ng/kg/min delivered
subcutaneously in rats [38]) leads to acutely increased BP in a
matter of minutes to hours and involves secretion of aldosterone,
retention of water and sodium, resetting of baroceptors, and
increased sympathetic output [38]. The use of different doses of
Ang II in thesemodels therefore offers the opportunity to compare
and contrast different pathways by which hypertension and end
organ damage develop and to delineate the effects of one mole-
cule at a multi-system level in an in vivo model. Using both sub-
pressor and pressor doses of Ang II also leads to direct effects,
whichmediate target end organ damage, including direct promo-
tion of cardiomyocyte hypertrophy, vascular hypertrophy, and
cardiac and renal fibrosis. The Ang II infusion model is therefore
useful for the study of hypertension and end organ damage
specifically in response to Ang II. By only altering one factor in
recipient animals the many different pathways regulated by Ang II
including vascular tone, tissue remodeling, inflammation and oxi-
dative stress can be studied. Although these models may not
recapitulate all of the complexities of essential hypertension in
patients, nonetheless they offer useful models to facilitate clearer
understanding of specific RAS-related pathways.
3.1.1. Proteomic studies in the Ang II infusion model of
hypertension and end organ damage
Relatively few studies to date have utilized the Ang II infusion
model to study proteomic changes in relation to the role of Ang
II in hypertension. Using a rat model of Ang II infusion, a direct
comparison of the effects of both pressor (60 ng/min) and sub-
pressor (15 ng/min) doses in renal proximal tubules via phospho-
proteomic screeningwas performed [40]. This led to profiling of 38
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phosphoproteins, including 14 that were only significantly altered
via the pressor doses, highlighting differences in the response to
sub-pressor andpressor doses ofAng II. Increasedphosphorylation
of protein kinase C (PKC) isoforms (PKCΦ061 and PKCβII), as well as
glycogen synthase kinases (GSK) 3Φ061 and β were detected.
Conversely, PKCσ and cAMP response element phosphorylation
was decreased. Following infusion of sub-pressor Ang II doses only
seven phosphoproteins were altered, including increased PKCα,
PKCσ and GSKα phosphorylation. These effects were sensitive to
blockade of the AT1R with the ARB losartan, and the data impli-
cated roles for PKC, GSK and cAMP signaling being important in
the renal response to Ang II infusion. Furthermore, utilizing AT1R
knockout mice in comparison to wild type mice, proteomics was
used to demonstrate that in the kidney of AT1R knock-outmice the
thiazide-sensitive co-transporter and amiloride-sensitiveNa+ trans-
porter were downregulated while the epithelial sodium channel
(ENaC) isoforms γ and β were significantly increased [41]. These
studies confirmed the importance of the AT1R in regulating
sodium transporters and ion channel proteins in the kidney.
These two publications highlight the important role of Ang II
signaling via the AT1R to regulate the renal response to changes
in electrolytes and fluid volume to maintain BP.
Using Fisher rats infused with a pressor dose of Ang II (450
ng/kg/min) for 14 days the platelet proteome was investigated
based on prior knowledge that hypertension is a risk factor for
arterial thrombosis [42]. In isolated and purified platelets 45
proteins, including talin-1, thrombospondin-1, transgelin-2,
and filamin-A were determined to show hypertension-asso-
ciated changes. All the proteins were normalized within
10 days of Ang II withdrawal and animals returning to normo-
tension. The authors concluded that these proteins may con-
stitute useful biomarkers for monitoring BP. Using Ang II
infusion in mice (50 ng/min), it was demonstrated that during
the development of hypertension high resolution proteomics
could be used to identify protein aggregates in the heart [43].
Identified proteins included ApoE, ApoJ, ApoAIV, clusterin, and
complement C3, all proteins previously implicated in aging-
associated fibrosis or aging-associated neurodegenerative
conditions. These findings highlighting that diverse disease
processes associated with fibrosis lead to changes in protein
aggregates, defining common proteomic changes that may be
associated with disease development. The effects of caloric
restriction on Ang II–induced cardiac damage and mitochon-
drial dysfunction was investigated using a double transgenic
rat expressing renin and angiotensinogen genes that leads to
endogenous elevated Ang II levels and hypertension [44]. In
this model, proteomic profiling of mitochondria isolated from
the hearts revealed changes in proteins associated with cytos-
keletal rearrangement, and oxidoreductase activity and pro-
vided evidence that calorie restriction could protect the
mitochondria from Ang II-induced damage and dysfunction.
3.1.2. Proteomics studies of the RAAS in cardiovascular
cell culture models
Proteomic screening has also been utilized in in vitro pri-
mary cell models related to hypertension to refine under-
standing of the effects of Ang II on individual cell types.
This may offer advantage of simplifying data analysis and
interpretation since despite the Ang II infusion model only
relying on altering levels of one molecule, the pleiotropic
effects of Ang II on a number of different pathways in a
range of different organs during the development of hyper-
tension highlights that it still results in the generation of
complex data sets. Using VSMC the Ang II-regulated secre-
tome was analyzed via proteomics [45]. In conditioned
media from VSMC stimulated with Ang II 629 proteins
were identified, with 26 being differentially expressed
between Ang II and control stimulated cells. Of the proteins
identified several were related to growth including clusterin
and growth arrest-specific 6, and were decreased in
response to Ang II. Other identified proteins including
cathepsin B, plasminogen activator inhibitor-1 (PAI-1) and
periostin were also demonstrated to be differentially
regulated.
An endogenous counter-regulatory axis of the RAAS exists
centered on an ACE homologue ACE2 and generation of the
active peptide hormone Ang-(1–7), which acts at the receptor
Mas and can antagonize pathophysiological effects of Ang II at
the AT1R (reviewed in McKinney et al. [46]). Using in vitro cell
culture models the first studies into the counter-regulatory
axis of the RAAS have been performed to identify novel sig-
naling mechanisms of the peptide hormone Ang-(1–7) [47].
The phosphoproteome of Ang-(1–7)-stimulated human aortic
endothelial cells was investigated and identified novel Ang-(1–
7) targets, including forkhead box protein O1 and proline rich
AKT1 substrate 1. Furthermore, the studies highlighted
changes in phosphorylation of downstream effectors of the
insulin signaling cascade, revealing a potential novel role for
Ang-(1–7) in regulating glucose homeostasis in endothelial
cells. A more recent study, also in human aortic endothelial
cells, revealed that Ang-(1–7) stimulated cofilin-1 expression
[48]. Cofilin-1 is known to be involved in regulating actin
filament dynamics and in cytokinesis [49] and has previously
been implicated in cancer progression [50]. Ang-(1–7) stimu-
lated G0/G1 arrest through a pathway involving cofilin 1,
suggesting its importance for maintaining cell cycle home-
ostasis in response to Ang-(1–7) [48].
In summary, the role of the RAAS and Ang II in the devel-
opment of hypertension in patients is well known and the
mechanisms are well conserved between humans and rodent
models. The development of the Ang II-infusion model of
hypertension has offered the opportunity to study the role
of Ang II in hypertension in isolation of other confounding
factors, such as environment, diet, and idiopathic genetic
influences. However, the broad range of concentrations of
Ang II utilized in studies across different timepoints, combined
with the range of effects of Ang II in different tissues means
data interpretation is complex. Although in vivo studies have
highlighted potential new molecules regulated by Ang II,
many of the general signaling pathways had already been
identified by targeted research. In in vitro models more spe-
cific questions can be asked and less complex data sets have
revealed novel signaling pathways in both the classical RAAS
and the counter-regulatory RAAS axis. Future research is
required to fully understand how these novel pathways con-
tribute to regulation of the RAAS in vivo in the development of
hypertension and to translate these findings into the patient.
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3.2. Spontaneously hypertensive rats as model of
human primary hypertension
The SHR is an inbred strain that is by far the most widely
studied model of human essential hypertension. The strain
was developed in Kyoto in the 1960s by selective inbreeding
for high blood pressure from outbred Wistar rats [51]. The SHR
is characterized by a number of phenotypic abnormalities,
including spontaneous hypertension, cardiac hypertrophy,
and vascular dysfunction [52]. Blood pressure begins to rise
between 5 and 6 weeks of age in SHR and becomes fully
established around 15–20 weeks of age [52]. The closely
related stroke prone SHR (SHRSP), displays more severe hyper-
tensive phenotype than the SHR, in addition to spontaneous
strokes and salt sensitivity [53,54].
3.2.1. Proteomic studies in the spontaneously hypertensive
rat
SHR have been extensively characterized at both the genomic
and phenotypic level [55–57], and the model has been used to
examine the proteome in a range of cardiovascular tissues.
Examples include a study by Jin et al. [58] that examined
protein expression changes occurring during development of
left ventricular hypertrophy, using 2D gel electrophoresis in
combination with matrix assisted laser desorption/ionization –
time of flight tandem mass spectrometry (MALDI-TOF/TOF MS/
MS) in left ventricular myocardium from SHR and normoten-
sive Wistar Kyoto (WKY) rats. They reported 13 proteins that
were differentially expressed in the SHR before the onset of
hypertension. These proteins included □-enolase and lactate
dehydrogenase B, which are two important enzymes for gly-
colysis, as well as proteins associated with mitochondrial oxi-
dative phosphorylation, oxidative stress and cellular energy
metabolism [8]. In addition, a study by Lee et al. [59] also
reported the use of 2D gel electrophoresis and MALDI-TOF/
TOF MS/MS to study protein expression profiles in aortic
smooth muscle of SHR and WKY rats. They identified seven
proteins that were differentially expressed between the
strains, including reduced expression of dihydropteridine
reductase (DHPR), which is associated with the regeneration
of tetra-hydrobiopterin (BH4) and is involved in the develop-
ment of vascular oxidative stress [60]. A recent study by
Hatziioanou et al. [61] that used 2D gel electrophoresis of
renal parenchyma from SHR and WKY rats identified overex-
pression of chloride intracellular channel 4 (CLIC4) protein in
the proximal tubule during early stages of hypertension devel-
opment. This finding suggests that CLIC4 may be a useful early
marker to detect renal tubular alterations in the development
of hypertensive nephrosclerosis.
The SHR has also been used to examine proteome impact
after pharmacological or physical intervention. For example,
proteomic changes occurring in the aorta as a result of physi-
cal activity-induced blood pressure reduction have been
demonstrated [62]. In this study, young SHR and WKY rats
were exposed to a 6-week load-free swimming program,
which significantly reduced blood pressure in the hypertensive
model. Proteomic analysis was carried out by LC-MS in aorta
from exercise-trained and sedentary SHR and WKY rats. When
compared with sedentary SHR rats, nine differentially
expressed proteins were identified, five were up regulated
(long-chain specific acyl-CoA dehydrogenase, heat shock pro-
tein β-1, isocitrate dehydrogenase subunit α, actin, α cardiac
muscle 1 preprotein, and calmodulin isoform 2) and four were
down regulated (adipocyte-type fatty acid-binding protein,
tubulin β-2C chain, 78 kDa glucose-regulated protein precur-
sor, and mimecan). This study confirms that proteomics is an
effective method to identify the target proteins of exercise
intervention for hypertension.
3.2.2. Beyond proteomics: multilevel omics and
integration of genetic information
A study by Low et al. [63] combined proteomics with in-depth
genomic and transcriptomic analysis allowing a multilevel
systems approach for identification of candidate genes
involved in the SHR hypertensive phenotype. In this study,
the liver proteome was compared between a specific subline
of the SHR (SHR/Olalpcv) and the Brown Norway rat (BN-Lx).
This multilevel approach identified 26,463 rat liver proteins,
and validated 1,195 gene predictions, 83 splice events, 126
proteins with nonsynonymous variants, and 20 isoforms with
nonsynonymous RNA editing. A major finding of this study
was the identification of a genomic variant in the promoter of
the Cyp17a1 gene, which is a previously reported top hit in
human genome wide association studies for hypertension.
In addition to examining tissue proteome differences between
inbred normotensive and hypertensive strains, there is huge
potential for studying downstream effects of specific geneticmod-
ifications. Studies of genetically modified rats can be used to
reduce the complexity of the proteomics analysis, where a single
gene or a restricted number of genes are responsible for the
observed phenotypic differences. An example of this reductionist
approach is the recent study by Manakov et al. [64], which com-
pared the cardiac proteome of SHR and transgenic SHR-Cd36 rats,
carrying a copy of the wild type CD36 gene. Protein expression
profiling was based on two-dimensional gel electrophoresis (2DE)
coupled to tandemmass spectrometry and label-free LC/MS in the
left and right heart ventricles of SHR and SHRCd36 rats. In total, 26
differently expressed myocardial proteins were identified, out of
which 18 were found in the right ventricles and 8 in the left
ventricles. This is the first report to reveal an impact of transgenic
expression of CD36 on the heart at the proteome level, identifying
down regulation of respiratory chain enzymes that suggests a shift
in regulation of energy metabolism.
Although the proteome is several orders of magnitude
more complex than the genome, it is vital for determining
how proteins interact as a system and for understanding the
function of cellular systems in disease. This snapshot of pro-
teomics studies in the SHR rat demonstrates the important
role that this model plays in understanding the mechanisms
underlying hypertension and its end-organ damage.
4. Human studies
4.1. Proteomic studies in human hypertension
We have already outlined that primary hypertension is a com-
plex cardiovascular condition that is defined by a physiological
parameter (blood pressure above a somewhat arbitrary
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threshold) and not by underlying pathophysiological princi-
ples, which can indeed be different between patients. This
complexity and heterogeneity of hypertension makes studies
into the pathogenesis of hypertension particularly difficult. In
contrast to proteomic approaches, genetic or genomic studies
can be done at any point in time as the genome remains
stable despite changes in the phenotype. With hypertension
being mainly a disease of the elderly [65], this is an advantage
of genetic over proteomic approaches as genetic variants can
already be detected at young age and predict the develop-
ment of hypertension later in life. However, proteomic studies
have the advantage of describing the current state of an
organism or its organs or tissues and thereby integrate genetic
and environmental factors. These considerations have already
been discussed previously by us [66,67] and others [68].
For the above reasons, there are very few studies that
define proteomic signatures of hypertension. An exemption
is a recent study Gajjala et al. [69] who employed a complex
proteomic workflow to discover plasma peptides that are
differentially expressed between normotensive and hyperten-
sive subjects. A proteomic score has been developed to differ-
entiate between patients and controls and includes a total of
27 molecular determinants, such as phosphoinositide 3-kinase
regulator 1, osteocalcin, and nexilin. Literature mining and
pathway analysis confirmed the involvement of these features
in atherogenesis, cellular calcium metabolism, cytoskeletal
organization, angiogenesis, and other key pathways that are
likely to play a role in the pathogenesis of hypertension. The
authors discussed that their analysis could not determine
whether the observed differences were a cause or conse-
quence of hypertension and referred to other studies that
face the same challenges [42,70].
Interestingly, a recent study by Johansson et al. [71]
employed targeted proteomic profiling using the Proximity
Extension Assay technique to study another blood pressure-
related condition: orthostatic hypotension. Plasma proteins
that were found to be differentially expressed between
patients and controls included matrix-metalloproteinase-7
(MMP-7), T-cell immunoglobulin, and mucin domain-1 (TIM-1)
and thereby proteins involved in matrix degradation and
inflammation – molecular features that have also been found
in studies into the pathophysiology of hypertension. It is
reasonable to assume that information about blood pressure
regulation can be obtained from proteomic studies at both
ends of the extreme, hypertension, and hypotension.
4.2. Proteomics and hypertension-associated organ
damage
As changes in the proteome directly relate to changes in organ
structure and function, proteomic techniques have been used to
study organ damage as a result of hypertension. Hypertension
affects a variety of organs including the brain, kidneys, eyes, and
large vessels and particularly the heart. Using capillary electro-
phoresis-mass spectrometry (CE-MS) Kuznetsova et al. [72] have
established urinary proteomic profiles that are associated with
left ventricular diastolic dysfunction, one of the earliest func-
tional markers of hypertensive heart disease. The urinary peptide
markers have been further shown to be differentially regulated
also in patients with overt heart failure, indicating a molecular
pathophysiological continuum from subclinical damage to overt
disease [72]. These data have been further confirmed in a larger
study in the general population demonstrating correlations
between left ventricular dysfunction and the urinary proteome
[73]. The urinary proteome can also provide information on
cardiovascular endpoints in hypertensive patients where it has
been found to predict coronary events in a substudy of the
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) [74]. A
more detailed review of the potential of proteomic studies in
cardiac remodeling has been published elsewhere by Petriz and
Franco [75].
Similar studies have been conducted in hypertensive
patients at risk of developing renal disease. Plasma proteomic
studies using LC-electrospray-trap MS have identified molecu-
lar signatures based on signaling molecules, growth factors,
and angiogenesis factors that are predictive of renal disease in
patients with hypertension and/or diabetes [76]. A compre-
hensive proteomic profiling study in 123 hypertensive patients
with chronic RAAS suppression has found signatures that pre-
dict development of de novo development of albuminuria or
indicate stable albuminuria [77]. The signatures were com-
posed of proteins involved in inflammation, immune, and
proteasome activation/endoplasmatic reticulum stress.
Further studies by these authors in urine samples [78] and
urinary exosomes [79] confirmed the link between inflamma-
tion and development of albuminuria in people with con-
trolled hypertension on RAAS blockade. The complementary
nature of these two studies using different sample types
increases the reliability of the data and paves the way to
further studies that can explore effects of therapeutic strate-
gies on proteomic signatures of immune dysregulation that
will translate into prevention of albuminuria and ultimately,
renal failure in patients with hypertension.
4.3. Proteomic studies in preeclampsia
While the number of proteomic studies in primary hyperten-
sion is relatively small and often focusses on studies into
hypertension-associated organ damage there are larger
amounts of data available in hypertension in pregnancy and
especially in pre-eclampsia. These conditions are particularly
attractive research areas for a number of reasons. First, they
have an important impact on health with preeclampsia being
a main reason for maternal and fetal morbidity and mortality.
Second, these conditions develop within the timeframe of
pregnancy with a defined start and stop point within less
than 9 months and can thereby be studied in their wholeness
as opposed to primary hypertension where development
spans many decades. Third, preeclampsia develops in pre-
viously healthy women and the changes in blood pressure
and the related changes in organs, such as the kidney can
be easily contrasted to women with normal course of preg-
nancy. While exact mechanisms of hypertension in pregnancy
may be different from those in essential hypertension, it can
be reasonably assumed that basic principles will overlap and
that data from hypertension in pregnancy will also inform
research into other cardiovascular conditions.
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Another advantage of research into hypertension in preg-
nancy is that these conditions, especially preeclampsia, are
thought to be driven by placental factors. Access to placenta
tissue post partum for molecular studies is much easier than
access to other human cardiovascular tissues. For example,
Zhang et al. [80] have used MS studies in placentas of
women with preeclampsia and controls with normal pregnan-
cies to describe proteins and protein networks that are
involved in cellular movement, development, growth, and
proliferation. Using a similar study design and a 2D LC-MS/
MS quantitative proteomics strategy, Jin et al. [81] have
demonstrated a number of differentially expressed proteins
between preeclamptic and normal placentas involved in
inflammation and defence against oxidative stress. In particu-
lar, alterations in proteins involved in glutathione metabolism
have been found to be characteristic of placentas from pre-
eclamptic women. A recent study by Mary et al. [82] demon-
strated differential regulation of haptoglobin and hemopexin
between preeclamptic and normal placentas. In contrast to
these studies in whole placenta, Ma et al. [83] have used
trophoblast cells obtained by laser capture microdissection
and demonstrated differences in 169 out of 831 proteins
identified by 2D LC-MS/MS of which downregulation of lami-
nin in trophoblastic cells of women with preeclampsia was the
most prominent finding.
A number of studies have used proteomic approaches in
biofluids, such as blood and urine to identify markers that
could predict the development of preeclampsia. Of these the
study by Myers et al. [84] who employed an integrated
approach of unbiased screening, targeted quantitation and
supplementation of models with known pathogenetic factors
to describe novel biomarkers for prediction of preeclampsia.
The most promising models centered on insulin-like growth
factor acid labile subunit. A urinary proteomic study by Chen
et al. [85] employed iTRAQ labeling coupled with 2D LC-MS/
MS and identified 113 differentially expressed proteins
between women with preeclampsia and those with normo-
tensive pregnancies. Urinary angiotensinogen has been found
downregulated in women with preeclampsia pointing toward
the critical role of the RAAS in the development of this con-
dition. Carty et al. [86] conducted a CE-MS-based study and
described urinary proteomic profiles in first trimester that
were different between women who later developed pree-
clampsia and those who continued to be normotensive; the
initial discoveries were, however, not validated in an indepen-
dent validation cohort.
5. Precision medicine and the role of proteomics in
hypertension
We have demonstrated that proteomic studies have the poten-
tial to discover pathophysiological principles that are involved in
the development of hypertension both in experimental models
and in humans. Compared to other approaches, including geno-
mic studies the progress in the proteomic field is, however, slow
despite the apparent potential of such studies [18]. In part this is
due to proteomics being a relatively young area of research and
the complexity not only of the proteome itself but also the
proteomic platforms that require specialist skills to acquire and
interpret the data. To large extent the slow progress is due to the
complexity of hypertension itself. This has already been apparent
in the first large genome-wide association study by the
Wellcome Trust Case-Control Consortium [87] where the study
of all other complex diseases resulted in significant and plausible
hits whereas not a single genetic variant achieved genome-wide
significance for hypertension. Only with changes in study
designs [88] and further increased sample sizes [89] have geno-
mic studies in hypertension evolved into a success story.
We do believe, however, that there is a degree of miscon-
ception when researchers try to find common pathological
principles across patients with complex and multifactorial dis-
eases. It is indeed the unique feature of such conditions that
different factors contribute to different extent to an indivi-
dual’s phenotype, and this contribution results from the inter-
play of genetic and environmental influences and can change
over time. Rather than using omics technologies primarily to
discover common pathophysiological features we would very
much like to encourage researchers to use these techniques to
precisely describe an individual’s molecular make-up at a
given point in time. Proteomics is ideally placed to deliver
on this task. A large number of proteins can be described in
tissue samples or body fluids and individual signatures or
fingerprints can be developed that will have the potential
not only to define a specific disease phenotype but also to
direct preventative and therapeutic measures in the spirit of
precision medicine [90].
In current clinical practice, there is very little stratification of
treatment in patients with hypertension and approaches often
follow trial and error principles. Exceptions are the prescription
of certain classes of antihypertensive drugs if they have addi-
tional benefits for co-existing conditions, e.g. ACE inhibitors to
treat hypertension and prevent progression of kidney disease
or beta blockers to treat hypertension and heart failure. Some
guidelines, such as those by The National Institute for Health
and Care Excellence (NICE) recommend the choice of initial
antihypertensive therapy based on age and ethnicity – surro-
gates of renin levels and RAAS activity [8,91]. The recently
published Prevention And Treatment of Hypertension With
Algorithm-based therapy (PATHWAY) 2 trial demonstrated
that treatment response to the mineralocorticoid receptor
antagonist spironolactone can be predicted by activity of the
RAAS as assessed by baseline renin levels [92]. We would
expect that a more individualized definition of hypertension
based on precise clinical phenotypes and supplemented by
biomarker and omics data could provide a much more power-
ful tool to predict a patient’s risk and offer the right preventa-
tive and therapeutic approaches at minimal cost and with
minimal side effects.
6. Expert commentary
Hypertension is a complex cardiovascular disorder. While in
the rarer secondary forms of hypertension the predominant
mechanisms that increase blood pressure are known, the more
common primary form of hypertension results from the inter-
action of multiple pathogenetic principles, such as oxidative
stress, endothelial dysfunction, inflammation and vascular
stiffening.
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Proteomic studies have the potential to discover new dis-
ease pathways and drug targets in hypertension despite the
complexity of the disease. However, the complexity of hyper-
tension and associated organ damage not only offers potential
but is also associated with challenges for proteomic and other
biomarker approaches. Therefore, studies in experimental
models are currently the mainstay of proteomic research in
hypertension. In our review we have focussed on two models
of hypertension that illustrate the approaches in hypertension
research. The Ang II infusion model represents a hypothesis-
driven approach with a single primary cause of hypertension.
It is particularly well suited to study the complex sequelae of a
single pathogenetic factor. Other models that mimic endo-
crine forms of hypertension, renal hypertension, or reduced
nitric oxide availability can complement this research and
unravel both common and model-specific pathways. In con-
trast, the SHR is a model of genetically determined hyperten-
sion that is multifactorial in origin. In this and other models of
primary hypertension proteomic techniques offer insight into
the interaction of pathogenetic principles that lead to the
phenotype of raised blood pressure.
Themajor hurdle at this point in time is, however, translation to
human hypertension. While numerous studies are available in
preclinical models there are few examples of validation of these
findings in patients with hypertension. This is mainly due to the
challenges related to tissue sampling in humans. Even if vascular,
renal or cardiac tissues are available in some cohorts and have
been successfully used for proteomic analyses, the absence of
serial (longitudinal) samples makes it impossible to easily dissect
cause and consequence of hypertension. While this challenge
applies not only to proteomics but also to other biomarker
approaches the complex nature and high costs of proteomics
make it more difficult to compensate for the lack of serial samples
by increasing the sample size of cross-sectional studies and adjust-
ing for clinical variables including duration of hypertension.
In clinical studies, researchers are therefore currently focussing
on consequences of hypertension including left ventricular hyper-
trophy and renal damage anduseproteomic approaches to under-
stand the transition from risk factor to organ damage both in the
natural progression of hypertension and in patients on treatment.
However, standardized approaches andmuch larger datasets than
those currently available, together with translational approaches
between experimental models and clinical practice will have to be
used to achieve meaningful results. We have witnessed the enor-
mous potential that genomics offered in complex diseases, such as
hypertension, coronary artery disease and diabetes but this suc-
cess is based on significant funding initiatives, international colla-
borations, standardized analysis methods, shared resources, and
very large numbers of biosamples. In parallel to studies in well-
defined preclinical models, the proteomic community needs to
scale up its efforts in order to bring proteomic techniques to
clinical research and practice.
7. Five-year view
The next five years will in all likeliness decide about the future
of proteomics in hypertension research. The potential of pro-
teomics in cardiovascular diseases has been recognized [18]
but there are almost no large-scale programs that employ a
standardized approach to the proteomics of hypertension.
Without such efforts the field of proteomics is unlikely to
make meaningful contributions to hypertension research,
although it will continue to play an important role in other
clinical conditions. We encourage the community to work
together and develop large programs into the proteomics of
hypertension to be ready for the era of precision medicine. We
would like to propose a workplan that can be initiated within
the next five years to make use of the opportunities that
proteomic research offers for patients with hypertension but
appreciate that it may take longer to fully deliver on this plan.
First, at the level of preclinical research we strongly believe
that complex datasets, such as data resulting from proteomic
studies cannot be analyzed in isolation but should be brought
together with already existing data in the same and in other
models. We have already witnessed the description of com-
mon molecular features across different models of hyperten-
sion and other cardiovascular diseases but call for stronger
collaborative approaches to compare and integrate datasets.
We expect that within the next five years there will be better
understanding of model-specific pathogenetic factors of
hypertension, as well as of shared pathways that are indepen-
dent of the initial cause.
Second, clinical proteomic studies need to be better coor-
dinated and larger in size so that reliable data can be
obtained. Previous experiences with suboptimal study designs
but also the general trend toward reduced availability of
funding for biomedical research will ‘force’ the proteomic
community to work together and to design impactful
research. The potential that samples from clinical trials and
large-scale repositories, such as the Framingham cohort or the
UK Biobank offer will support large-scale proteomic
approaches. We expect that in the first instance targeted
proteomic studies will be conducted that offer large through-
put at limited costs but also at low resolution. Such studies are
indeed currently underway and will be reported within the
next five years and support large-scale projects into untar-
geted proteomics in the longer term.
Third, and as a result of the above steps, we expect that
proteomics will play a critical role in precision medicine in the
future. In fact, the majority of biomarkers that are being used
in clinical practice to stratify risk or diagnose disease are
protein or peptide biomarkers (including e.g. cardiac troponins
and natriuretic peptides) and there is no reason why a wider
array of protein biomarkers should not be suited to better
define an individual’s molecular make-up and thereby support
decisions based on the principles of precision medicine.
Clearly the full potential of proteomics can only develop if
data are integrated with precise clinical phenotypes, other omics
data and other biomarkers. We will see further development of
bioinformatics and systems biology to support data analysis.
Again, this is not unrealistic to happen within the next five
years as long as sufficient amounts of high-quality data will be
generated. He rapid development of tools to analyze genomic
data is an excellent example of the available opportunities. Only
then proteomic research can translate into diagnostic and ther-
apeutic approaches in patients with hypertension, targeting key
tissues, including the endothelium, heart, and kidneys.
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Key issues
● Hypertension is a multifactorial condition that develops
over a long period of time and is defined based on clinical
criteria rather than on pathophysiological principles.
● Proteomic studies have been conducted to define molecu-
lar features of hypertension in experimental models and
clinical studies. Proteins involved in angiogenesis, vasocon-
striction, inflammation, and matrix degeneration have been
repeatedly found in such studies.
● The majority of research studies focusses on proteomic
signatures of hypertension-associated organ damage, such
as heart failure and renal disease.
● The currently available studies are relatively small, not stan-
dardized, difficult to compare across each other and there-
fore cannot compete with much larger efforts in other
omics disciplines, including genomics and metabolomics.
● Despite the challenges related to the disease itself and also
to proteomics as a tool there is an enormous potential for
proteomics to inform precision medicine approaches in the
management of hypertension.
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